Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-10-15
2011-10-25
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C530S387900, C530S388220
Reexamination Certificate
active
08043618
ABSTRACT:
The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner
patent: 2005/0147612 (2005-07-01), Yayon
patent: 2007/0248605 (2007-10-01), Hestir
patent: 2010/0003258 (2010-01-01), Weng
patent: 1423428 (2004-02-01), None
patent: 8809344 (1988-12-01), None
patent: 02102972 (2002-12-01), None
patent: 2005066211 (2005-07-01), None
Portolano et al. Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by Human H and L chain “roulette”. The Journal of Immunology, vol. 150/3:880-887 (1993).
Clackson et al. Making antibody fragments using phage display libraries. Nature, vol. 352 (Aug. 1991).
Pascalis et al. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. The Journal of Immunology, vol. 169:3076-3084 (2002).
Dominiques-Escig et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clinical Cancer Research 10:4874-4884 (Jul. 2004).
Singh et al. Oral silibinin in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clinical Cancer Res 14(1) (Jan. 2008).
Hsi et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res 14:2775-2784 (May 2008).
Martin, A.C.R. Accessing the Kabat Antibody Sequence Database by Computer PROTEINS: Structure, Function and Genetics, 25, 130-133 (1996).
Dvorak, et al., Increased expression of fibroblast growth factor receptor 3 in CD34+BCR-ABL+cells from patients with chronic myeloid leukemia, Leukemia 17(12):2418-2425 (2003).
Keegan, et al., Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3, Proc. Natl. Acad. Sci. 88:1095-1099 (1991).
Scotet, et al., The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific, Biochimica Et Biophysica Acta 1264(2):238-242 (1995).
Abath, et al., A Simple Method for the Recovery of Purified Recombinant Peptides Cleaved from Glutathione-S-Transferase-Fusion Proteins, Peptide Research 3(4):167-168 (1990).
Batley, et al., Inhibition of FGF-1 Receptor Tyrosine Kinase Activity by PD 161570, a New Protein-Tyrosine Kinase Inhibitor, Life Sci. 62:143-150 (1998).
Boerner, et al., Production of Antigen-Specific Human Monoclonal Antibodies from In Vitro-Promed Human Splenocytes, J. Immunol. 147(1):86-95 (1991).
Intentionally Omitted [Campbell, Monoclonal Antibody Technology. The Production and Charaterization of Rodent and Human Hybridomas, Elsevier Science Publishers, Amsterdam, New York (1984)].
Chellaiah, et al., Mapping Ligand Binding Domains in Chimeric Fibroblast Growth Factor Receptor Molecules, J. Biol. Chem 274(49):34785-34794 (1999).
Chothia, et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol. 196 (4):901-917 (1987).
Cole, et al., The EBV-Hybridoma Technique and Its Application to Human Lung Cancer, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc. pp. 77-96 (1985).
Deevi, et al., AACR Abstract No. 2329, Mechanism for the Benefits of Cetuximab in Combination with Oxaliplatin, in Oxaliplatin Sensitive and Resistant Colon Cancer Cell Lines (Oct. 21-24, 2007).
Dieckmann, et al., Assembly of the Mitochondrial Membrane System, J. Biol. Chem. 260:1513-1520 (1985).
Hawkins, et al., Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation, J. Mol. Biol., 226:889-896 (1992).
Hoogenboom, et al., By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline Vh Gene Segments Rearranged in Vitro, J. Mol. Biol. 227(2):381-388 (1992).
Huse, et al., Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda, Science 246:1275-1281 (1989).
Kabat, et al., Attempts to Locate Complementarity-Determining Residues in the Variable Positions of Light and Heavy Chains, Ann. NY Acad. Sci. 190:382-393 (1971).
Kabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, No. 91-3242 (1991), Table of Contents Only pp. iii-xi.
Kohler, et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature 256:495-497 (1975).
Low, et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain, J. Mol. Biol. 250:359-368 (1996).
Marks, et al., By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage, J. Mol. Biol. 222(3):581-597 (1991).
Martin, A.C.R. Accessing the Kabat Antibody Sequence Database by Computer, PROTEINS: Structure, Function and Genetics, 25, 130-133 (1996).
Martinez-Torrecuadrada, et al., Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation, Clin. Cancer Res.;11 (17):6280-6290 (2005).
Panek, et al., In Vitro PHarmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor, J. Pharmacol. Exp. Ther. 283:1433-1444 (1997).
Qing, et. al., Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice, Journal of Clinical Investigation 119 (5):1216-1229 (2009).
Rauchenberger, et al., Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3, J. Biol. Chem. 278(40):38194-38205 (2003).
Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Chapter 1-18, Cold Spring Harbor Laboratory Press (1989), Table of Contents Only pp. xi-xxxviii.
Smith, et al., Single-Step Purification of Polypeptides Expressed inEscherichia colias Fusions with Glutathione S-transferase, Gene 67(1):31-40 (1988).
Direnzo, et al., Neutralizing antibody against FGFR3 shows anti-tumor effects in multiple tumor models in vivo, AACR Abstract No. 2080, Los Angeles, CA (Apr. 2007).
Wang, et al., Transcriptome analysis method for in vivo mechanism of action study: IMC-D11 anti-FGFR3 +/− cisplatin in bladder cancer models, AACR-EORTC Abstract No. 200, Geneva, Switzerland (Nov. 2008).
Deevi, et al., Inhibiting FGFR3 for enhancing the cytotoxic effects of cisplatin on bladder cancer cells and possible mechanisms, AACR-EORTC Abstract No. B48, San Francisco, CA (Oct. 2007).
Trudel, et al., The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells, Blood 107(10):4039-4046 (2006).
Wu, et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, J. Mol. Biol., 294:151-162 (1999).
Xin, et al., CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3—Expressing Orthotopic Multiple Myeloma Model in Mice, Clin Cancer Res. 12(16):4908-4915 (2006).
Yang, et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range, J. Mol. Biol. 254:392-403 (1995).
Liu Ling
Sun Haijun
Allen Marianne P
Deberry Regina M
Hason Averie K.
ImClone LLC
LandOfFree
Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295124